Anteris reports Q3 2025 cash burn; FDA OK to start PARADIGM trial in US

Anteris Technologies Global Corp.

2025-Q3 EPS reported -$1.80 vs consensus -$0.58 ▼ miss (-209.9%)

FDA approved U.S. recruitment for PARADIGM Trial in Nov 2025; first patients treated in Denmark in Oct 2025.
Q3 2025: R&D expenses $16.8M, SG&A $5.8M; net operating cash outflow 9M $59.3M.
Cash and cash equivalents $9.1M as of Sep 30, 2025.
IPO net proceeds $80M used: $52.7M for DurAVR development, $18.3M for debt repayment and working capital.
Related party payments in Q3: $515k (director fees, CEO, CFO remuneration).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.